Nykode Therapeutics ASA
Net BuyingNYKD·XOSL·🇳🇴 NO
67%buys·33%sells
64 transactions$0Total buys·14 buys
$0Total sells·7 sells
2929 insiders
Last: Jan 30, 2026
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Jan 30, 26 | Susanne Stuffers | Other | - | |
| Jan 30, 26 | John Beadle | Other | - | |
| Jan 30, 26 | Barbara Krebs-Pohl | Other | - | |
| Jul 9, 25 | Ulrich Blaschke | Other | - | |
| Jul 9, 25 | Agnete B. Fredriksen | Other | - | |
| Jul 9, 25 | Harald Gurvin | Other | - | |
| Jul 9, 25 | Michael Engsig | Other | - | |
| Jul 1, 24 | Louise Stubbe | Other | - | |
| Jul 1, 24 | Klaus Edvardsen | Other | - | |
| Jul 1, 24 | Agnete B. Fredriksen | Other | - |
Nykode Therapeutics ASA (NYKD) has recorded 64 insider transactions from 29 insiders. Total insider buying volume stands at $0, while total selling volume is $0. Overall insider sentiment is bullish (67% purchases).
Nykode Therapeutics ASA (NYKD) has recorded 64 insider operations, including 14 open-market purchases ($0), 7 sales ($0) and 43 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bullish (67% purchases).
Recent activity is concentrated over 2 months in the last year.
Among the most active insiders are Anders Tuv (BOARD MEMBER), Datum AS (CLOSE ASSOCIATE) & Axe Invest AS (CLOSE ASSOCIATE), with respectively 3, 2, 1 transactions.
Across all 64 recorded transactions, the breakdown by type is: grant (22, 34%), buys (14, 22%), other (14, 22%), sells (7, 11%), exercise (3, 5%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Nykode Therapeutics ASA has recorded 64 insider operations in total, including 14 open-market purchases ($0), 7 sales ($0) and 43 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on January 30, 2026.
Insiders at Nykode Therapeutics ASA are currently net buyers, with 67% purchases and 33% sales across all reported transactions. Total buy volume is $0 versus $0 in sales, indicating a bullish insider sentiment.
InsiderLens tracks 29 insiders at Nykode Therapeutics ASA (NYKD). Anders Tuv (BOARD MEMBER, 3 tx), Datum AS (CLOSE ASSOCIATE, 2 tx), Axe Invest AS (CLOSE ASSOCIATE, 1 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for NYKD is bullish, based on a 67% buy ratio across 21 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Nykode Therapeutics ASA comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.